Cost-effectiveness analysis of EGFR T790M mutant testing after acquired resistance to 1st/2nd generation EGFR-TKI in unresectable/recurrent non-small cell lung cancer
Not Applicable
Completed
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000038892
- Lead Sponsor
- The University of Tokyo, Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients treated with immunocheckpoint inhibitors after acquired resistance 1st/2nd generation EGFR-TKI 2) patients received at least 1 regimen of anti tumor therapy within 3 months prior to initiation of 1st/2nd generation EGFR-TKI treatment 3) complicated by haemophilia 4) complicated by leukaemia 5) complicated by severe heart failure
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ICER of EGFR T790M mutant testing
- Secondary Outcome Measures
Name Time Method Time to treatment failure (TTF), Overall survival (OS), Cost